ZFC3H1 as an Indicator of Poor Prognosis in Hepatocellular Carcinoma: Bioinformatic Analysis and Experimental Verification
- 1 August 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 28 (13) , 2263-2278
Abstract
Background: Zinc finger C3H1-type containing (ZFC3H1) might regulate RNA processes. However, research lacks the prognostic value of ZFC3H1 in hepatocellular carcinoma (HCC). Methods: The study analyzed ZFC3H1 expression in HCC cells and its correlation with patient prognosis using transcriptomics, immunohistochemistry, and quantitative real-time reverse transcription PCR, as well as single-cell RNA expression data. Additionally, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were used to investigate the potential ZFC3H1-related cellular functions and signaling pathways. The impact of ZFC3H1 expression on the tumor microenvironment and tumor mutational burden (TMB) was assessed using the ESTIMATE algorithm. Cell-based assays, including cell counting kit 8, proliferation, colony formation, cell cycle, wound healing, and Transwell assays, were conducted to evaluate the influence of ZFC3H1 on hepatocellular carcinoma proliferation and migration. Results: ZFC3H1 is upregulated in HCC and linked to tumor progression. High ZFC3H1 expression is a prognostic risk factor for HCC, according to Kaplan-Meier and Cox regression analyses. ESTIMATE analysis suggested that ZFC3H1 reduces immune cell infiltration and increases the TMB. Patients with low ZFC3H1 expression might respond better to immunotherapy. High ZFC3H1 expression is associated with increased half-maximal inhibitory concentration (IC50) of sorafenib. Functional experiments demonstrated that reducing ZFC3H1 expression inhibited HCC cell proliferation and migration. Conclusion: ZFC3H1 is upregulated in HCC, promoting the proliferation and migration of liver cancer cells, impacting the prognosis of HCC patients and the effectiveness of immunotherapy. ZFC3H1 might serve as a therapeutic target and biomarker for HCC.Keywords
Funding Information
- National key research and development program (2022YFA1104600)
- Key Science and Technology Program of Zhejiang Province (WKJ-ZJ-1818)
This publication has 36 references indexed in Scilit:
- Zinc finger C3H1-type containing serves as a novel prognostic biomarker in human pan-cancerGene, 2022
- SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathwayHepatobiliary & Pancreatic Diseases International, 2022
- The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerCancer Cell, 2020
- Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinomaHPB, 2020
- Biomarkers for Hepatobiliary CancersHepatology, 2020
- Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome AtlasCell Reports, 2019
- The RNA Exosome Adaptor ZFC3H1 Functionally Competes with Nuclear Export Activity to Retain Target TranscriptsCell Reports, 2018
- Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatmentMedicinal Research Reviews, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior?Journal of Cellular Physiology, 2016